A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria

• •Inclusion:
• •Adult subjects with previously treated recurrent CLL who have measurable lymphadenopathy
• •Require therapy for CLL
• •Have experienced CLL progression \< 24 months since the completion of the last prior therapy
• •Currently not sufficiently fit to receive cytotoxic therapy because of chemotherapy-induced bone marrow damage or comorbidities.